clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia
NICE guidance
Summary (source: NICE)
Reference: MIB278
Type: NICE guidance
Published: 30 November 2021
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia is nice guidance MIB278, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 30 November 2021. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.